16 Jun 2010 07:00
PuriCore Appoints Chris Wightman Executive Chairman
MALVERN, PENNSYLVANIA, AND LONDON, UK, 16 June 2010 - PuriCore (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces the appointment of Chris Wightman as Executive Chairman. Non-Executive Chairman since 2002, Wightman, based in the UK, will assume responsibility for the Company's long-term strategy and investor relations. This appointment will enable Greg Bosch, CEO, based in the US, to focus more time on the operational delivery of the Company's business plans.
Chris Wightman, Executive Chairman, said:
"Given the increasing challenges of managing the UK listing from the US as our two core businesses continue to expand, this change will enable the Company to capitalize on the Executives' complementary strengths and geographic locations. As a result, PuriCore will increase focus on the tasks of driving profit and margin in the Company's operating businesses and improving the visibility of the Company's technology and potential amongst existing and future shareholders."
Enquiries:
| Financial Dynamics | PuriCore |
| Susan Quigley | Chris Wightman, Executive Chairman, +44 (0) 20 7290 3445 |
| Ben Brewerton | Greg Bosch, CEO, +1 484 321 2700 |
| +44 (0) 20 7831 3113 |
|
About PuriCore
PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.